MHC‐linked susceptibility to a bacterial infection, but no MHC‐linked cryptic female choice in whitefish

Non‐random gamete fusion is one of several potential cryptic female choice mechanisms that have been postulated and that may enhance the survival probability of the offspring. Previous studies have found that gamete fusion in mice is influenced by genes of the major histocompatibility complex (MHC)...

Full description

Saved in:
Bibliographic Details
Published inJournal of evolutionary biology Vol. 17; no. 1; pp. 11 - 18
Main Authors Wedekind, C., Walker, M., Portmann, J., Cenni, B., Müller, R., Binz, T.
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Publishing Ltd 01.01.2004
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Non‐random gamete fusion is one of several potential cryptic female choice mechanisms that have been postulated and that may enhance the survival probability of the offspring. Previous studies have found that gamete fusion in mice is influenced by genes of the major histocompatibility complex (MHC) region. Here we test (i) whether there is MHC‐dependent gamete fusion in whitefish (Coregonus sp.) and (ii) whether there is a link between the MHC and embryo susceptibility to an infection by the bacterium Pseudomonas fluorescens. We experimentally bred whitefish and reared sibships in several batches that either experienced or did not experience strong selection by P. fluorescens. We then determined the MHC class II B1 genotype of 1016 surviving larvae of several full sibships. We found no evidence for MHC‐linked gamete fusion. However, in one of seven sibships we found a strong connection between the MHC class II genotype and embryo susceptibility to P. fluorescens. This connection was still significant after correcting for multiple testing. Hence, the MHC class II genotype can considerably influence embryo survival in whitefish, but gamete fusion seems to be random with respect to the MHC.
Bibliography:Mirjam Walker, Institute for Parasitology, University of Bern, 3012 Bern, Switzerland.
Present address
Bruno Cenni, Novartis Pharma AG, 4002 Basel, Switzerland.
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:1010-061X
1420-9101
DOI:10.1046/j.1420-9101.2004.00669.x